⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Nintedanib (Ofev) (nintedanib) | Accelerate Your Fibrosis Research

Home/Drugs/Nintedanib (Ofev)

Nintedanib (Ofev)

nintedanib

Approved

Sponsor: Boehringer Ingelheim

Indication: IPF / SSc-ILD

Mechanism of Action

Multi-kinase inhibitor targeting VEGFR, FGFR, and PDGFR pathways

Target: VEGFR, FGFR, PDGFR

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT01441297

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

Phase:PHASE2Org:National Cancer Center, Korea

COMPLETED

Relevant Publications (PubMed)

Development and Evaluation of Benzofuran Oxoacetic Acid Compounds as EPAC1 Activators.

Morgan D, Wiejak J, Powell FG et al.

J Med Chem2026 Mar 13

Nintedanib Lacks Efficacy in a Spirometry-Confirmed and Bleomycin-Induced Mouse Model of Idiopathic Pulmonary Fibrosis.

Bousamaki J, Maciag G, Petersen AG et al.

Basic Clin Pharmacol Toxicol2026 Apr

Industry Payments and Prescribing Patterns of Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis in the United States.

Murayama A, Tarras ES, Freeman LM et al.

Respir Med2026 Mar 11

Effects of the WNT signaling pathway on inflammation and fibrosis in idiopathic pulmonary fibrosis: Clinical, radiological and molecular evaluation.

Validated Models

This drug has been validated in the following preclinical models:

NCT05321069

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Phase:PHASE3Org:Boehringer Ingelheim

TERMINATEDNCT02780700

Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

Phase:PHASE2Org:Boehringer Ingelheim

COMPLETEDNCT02182219

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

Phase:PHASE1Org:Boehringer Ingelheim

COMPLETEDNCT02308553

Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma

Phase:PHASE1, PHASE2Org:University Hospital, Essen

View all trials on ClinicalTrials.gov

Kaya İ, Sezgin AK, Gündüz MK et al.

Exp Ther Med2026 Apr

Dynamic in vitro platform for mechanical profiling of human pulmonary aciniform organoids via intraluminal access.

Ikeo S, Tani Y, Sawayama J et al.

Biomaterials2026 Feb 26

View more on PubMed